中银证券给予佰仁医疗买入评级上半年营收稳定增长研发成果逐步落地

每日经济新闻08-22

中银证券08月22日发布研报称，给予佰仁医疗（688198.SH，最新价：94.98元）买入评级。评级理由主要包括：1）公司发布2024年半年报，2024H1公司实现营业收入稳定增长，三大核心业务超额完成业绩目标，同时研发费用大幅提升，强力推进各个研发项目，核心产品的研发和注册进展顺利，随着研发成果逐步落地，有望为公司带来业绩新增量；2）2024H1营业收入稳定增长，研发投入力度持续加大；3）三大...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461736461?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-22 16:16","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2461736461","market":"sh","top_or_hot":-1,"title":"中银证券给予佰仁医疗买入评级 上半年营收稳定增长 研发成果逐步落地","media":"每日经济新闻","content":"<div>\n<p>中银证券08月22日发布研报称，给予佰仁医疗（688198.SH，最新价：94.98元）买入评级。评级理由主要包括：1）公司发布2024年半年报，2024H1公司实现营业收入稳定增长，三大核心业务超额完成业绩目标，同时研发费用大幅提升，强力推进各个研发项目，核心产品的研发和注册进展顺利，随着研发成果逐步落地，有望为公司带来业绩新增量；2）2024H1营业收入稳定增长，研发投入力度持续加大；3）三大...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082216212595b34810&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中银证券给予佰仁医疗买入评级 上半年营收稳定增长 研发成果逐步落地</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中银证券给予佰仁医疗买入评级 上半年营收稳定增长 研发成果逐步落地\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-22 16:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082216212595b34810&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中银证券08月22日发布研报称，给予佰仁医疗（688198.SH，最新价：94.98元）买入评级。评级理由主要包括：1）公司发布2024年半年报，2024H1公司实现营业收入稳定增长，三大核心业务超额完成业绩目标，同时研发费用大幅提升，强力推进各个研发项目，核心产品的研发和注册进展顺利，随着研发成果逐步落地，有望为公司带来业绩新增量；2）2024H1营业收入稳定增长，研发投入力度持续加大；3）三大...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082216212595b34810&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688198","symbol_name":"佰仁医疗","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082216212595b34810&s=b","article_id":"2461736461","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082216212595b34810&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2461736461","pubTimestamp":1724314560,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"中银证券08月22日发布研报称，给予佰仁医疗（688198.SH，最新价：94.98元）买入评级。评级理由主要包括：1）公司发布2024年半年报，2024H1公司实现营业收入稳定增长，三大核心业务超额完成业绩目标，同时研发费用大幅提升，强力推进各个研发项目，核心产品的研发和注册进展顺利，随着研发成果逐步落地，有望为公司带来业绩新增量；2）2024H1营业收入稳定增长，研发投入力度持续加大；3）三大业务超额完成既定销售目标，产品市场竞争力凸显；4）加快实现研发成果落地，看好未来业绩增量空间。风险提示：产品研发失败风险，产品销售不及预期风险，带量采购政策变动风险。（文章来源：每日经济新闻）","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate","earning"],"viewcount":null,"language":"zh","relate_stocks":{"601696":"中银证券","688198":"佰仁医疗"},"translate_title":"Bank of China Securities gave Bairen Medical a buy rating, revenue grew steadily in the first half of the year, and R&D results were gradually implemented","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601696":1,"688198":1},"content_text":"中银证券08月22日发布研报称，给予佰仁医疗（688198.SH，最新价：94.98元）买入评级。评级理由主要包括：1）公司发布2024年半年报，2024H1公司实现营业收入稳定增长，三大核心业务超额完成业绩目标，同时研发费用大幅提升，强力推进各个研发项目，核心产品的研发和注册进展顺利，随着研发成果逐步落地，有望为公司带来业绩新增量；2）2024H1营业收入稳定增长，研发投入力度持续加大；3）三大业务超额完成既定销售目标，产品市场竞争力凸显；4）加快实现研发成果落地，看好未来业绩增量空间。风险提示：产品研发失败风险，产品销售不及预期风险，带量采购政策变动风险。（文章来源：每日经济新闻）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461736461"}

中银证券给予佰仁医疗买入评级 上半年营收稳定增长 研发成果逐步落地

精彩评论

中银证券给予佰仁医疗买入评级上半年营收稳定增长研发成果逐步落地